Data edition of
Residue An evidence-graded reference for peptide science

Tesamorelin clinical trials

Every study registered on ClinicalTrials.gov that lists Tesamorelin as an intervention, as of the data edition — what is being tested, in whom, by whom, and how far it has got.

Registered studies
24
Active or recruiting
3
Completed
14
With posted results
10
Planned or actual enrollment
2,068participants, summed
Registered studies of Tesamorelin by phase and status
PhaseStudiesBreakdown
Phase 1 2
2 completed, 0 active or recruiting, 0 stopped, 0 other
Phase 2 10
5 completed, 3 active or recruiting, 2 stopped, 0 other
Phase 3 2
2 completed, 0 active or recruiting, 0 stopped, 0 other
Phase 4 2
0 completed, 0 active or recruiting, 2 stopped, 0 other
Not applicable 5
4 completed, 0 active or recruiting, 1 stopped, 0 other
Observational 3
1 completed, 0 active or recruiting, 2 stopped, 0 other
Figure 1. 24 studies on ClinicalTrials.gov match the registry search tesamorelin. Multi-phase studies are counted at their highest phase. Open the full trial feed

Conditions studied

  1. Lipodystrophy4
  2. HIV4
  3. Abdominal Obesity3
  4. Mild Cognitive Impairment3
  5. HIV Infections2
  6. Aging2
  7. HIV Lipodystrophy2
  8. Growth Hormone Deficiency2
  9. Healthy Volunteers1
  10. HIV-1-infection1
  11. Frailty1
  12. Impaired Physical Function1

Lead sponsors

  1. Massachusetts General Hospital9
  2. Theratechnologies7
  3. Johns Hopkins University2
  4. University of Washington1
  5. Columbia University1
  6. University of California, San Diego1
  7. National Institute of Nursing Research (NINR)1
  8. Hudson Biotech1

The registry, study by study

Registration is not evidence of benefit; many registered studies never publish. Status and dates are as reported by sponsors to ClinicalTrials.gov.

Status
Phase

24 shown

Registered studies of Tesamorelin
StudyPhaseStatusStartnSponsor
NCT07481734Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) Phase 2 Recruiting Feb 2026 120 Hudson Biotech
NCT06554717Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV Phase 2 Recruiting Jul 2025 100 Massachusetts General Hospital
NCT03150511Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury Phase 2 Recruiting Jun 2018 36 Johns Hopkins University
NCT03826160Growth Hormone Dynamics and Cardiac Steatosis in HIV Observational Completed Jan 2019 23 Massachusetts General Hospital
NCT03375788Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular RiskResults posted Phase 2 Completed Jan 2019 51 Massachusetts General Hospital
NCT03226821Body Composition and Adipose Tissue in HIVResults posted Phase 4 Terminated Feb 2018 6 Columbia University
NCT02553603The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment Phase 1 Completed Jul 2017 22 The University of Texas Medical Branch, Galveston
NCT02572323Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected PersonsResults posted Phase 2 Completed Feb 2017 73 University of California, San Diego
NCT02931474Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia Phase 2 Withdrawn Oct 2016 0 National Institute of Nursing Research (NINR)
NCT02196831Tesamorelin Effects on Liver Fat and Histology in HIVResults posted N/A Completed Jul 2015 61 Massachusetts General Hospital
NCT01632592Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue N/A Withdrawn Jan 2014 0 Massachusetts General Hospital
NCT01579695Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Observational Terminated Feb 2013 391 Theratechnologies
NCT01591902Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® Phase 4 Terminated Jun 2012 129 Theratechnologies
NCT01788462Egrifta Replacement and Sleep Disordered Breathing Observational Withdrawn May 2012 0 Johns Hopkins University
NCT01388920Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle WastingResults posted Phase 2 Terminated Sep 2011 3 Theratechnologies
NCT01263717Effects of Growth Hormone Releasing Hormone in HIVResults posted N/A Completed Dec 2010 54 Massachusetts General Hospital
NCT00850564Effect of Short Term Growth Hormone Releasing Hormone in Healthy MenResults posted N/A Completed Feb 2009 15 Massachusetts General Hospital
NCT00795210Effects of Short-term Growth Hormone in HIV-infected PatientsResults posted N/A Completed Feb 2009 25 Massachusetts General Hospital
NCT00675506Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are ObeseResults posted Phase 2 Completed Jul 2008 60 Massachusetts General Hospital
NCT02012556Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients Phase 1 Completed May 2008 18 Theratechnologies
NCT00608023TH9507 Extension Study in Patients With HIV-Associated LipodystrophyResults posted Phase 3 Completed Aug 2007 263 Theratechnologies
NCT00257712SMART: Somatotrophics, Memory, and Aging Research Trial Phase 2 Completed Feb 2006 151 University of Washington
NCT00123253TH9507 in Patients With HIV-Associated Lipodystrophy Phase 3 Completed Jun 2005 412 Theratechnologies
NCT01264497Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes Phase 2 Completed Feb 2002 55 Theratechnologies

Run this search on ClinicalTrials.gov → Query term: tesamorelin